Prostate cancer is one of the more heterogeneous tumour types. In recent years, with the
rapid development of single-cell sequencing and spatial transcriptome technologies …

The emergence of resistance to prostate cancer (PCa) treatment, particularly to androgen
deprivation therapy (ADT), has posed a significant challenge in the field of PCa …

Cancer stem cells (CSCs) are the most important cause of cancer treatment failure.
Traditional cancer treatments, such as chemotherapy and radiotherapy, damage healthy …

Background The androgen receptor (AR) is a drug target used to inhibit AR and prostate
cancer (PCa) growth. Surprisingly, treatment with supraphysiological androgen level (SAL) …

TP53, functioning as the keeper of the genome, assumes a pivotal function in the inhibition
of tumorigenesis. Recent studies have revealed that p53 regulates ferroptosis pathways …

Abstract Background Prostate cancer (PCa) is a prevalent malignancy in men worldwide,
ranking as the second leading cause of cancer-related death in Western countries. Various …

Background Prostate cancer (PCa) is an age-associated malignancy with high morbidity and
mortality rate, posing a severe threat to public health. Cellular senescence, a specialized …

Despite many advances, prostate cancer (PCa) is still the second most frequently diagnosed
cancer and fifth leading cause of cancer death in men worldwide. So far, the promising field …

Aging exhibits several hallmarks in common with cancer, such as cellular senescence,
dysbiosis, inflammation, genomic instability, and epigenetic changes. In recent decades …

This comprehensive review navigates the complex relationship between cellular aging,
senescence, and cancer, unraveling the determinants of cellular fate. Beginning with an …